Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Above 50-Day Moving Average – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $8.10 and traded as high as $8.32. Capricor Therapeutics shares last traded at $8.24, with a volume of 4,395,381 shares.

Wall Street Analyst Weigh In

Several brokerages have commented on CAPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Friday, September 11th. JonesTrading lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. HC Wainwright cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, July 27th. Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $30.25.

Capricor Therapeutics Price Performance

The company has a fifty day simple moving average of $8.10 and a 200-day simple moving average of $20.43. The company has a market cap of $479.07 million, a P/E ratio of -3.36 and a beta of 0.80.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). On average, analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently modified their holdings of the stock. Activest Wealth Management increased its stake in Capricor Therapeutics by 100.0% in the 3rd quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 2,000 shares in the last quarter. KBC Group NV acquired a new stake in Capricor Therapeutics during the 1st quarter worth about $44,000. VestGen Advisors LLC purchased a new stake in Capricor Therapeutics during the third quarter valued at about $191,000. SG Americas Securities LLC purchased a new stake in Capricor Therapeutics during the first quarter valued at about $193,000. Finally, SBI Securities Co. Ltd. lifted its stake in Capricor Therapeutics by 834.6% during the third quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 23,495 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.